Targeted Therapy for Colorectal Cancer.

Area of Science:

• Oncology
• Genetics
• Cancer Research

Background:

• Metastatic colorectal cancer (mCRC) is largely incurable with unresectable disease.
• Systemic chemotherapy is the primary palliative treatment for most mCRC patients.
• Genomic profiling identifies mutations for targeted therapy, offering modest survival benefits.

Purpose of the Study:

• To outline current treatment strategies for unresectable metastatic colorectal cancer.
• To highlight the role of genomic profiling in guiding therapy selection.
• To review the efficacy of targeted therapies and immunotherapy in mCRC.

Main Methods:

• Review of clinical trial data and treatment guidelines for mCRC.
• Analysis of targeted therapy efficacy based on specific mutations (RAS, BRAF).
• Evaluation of immunotherapy in microsatellite instability-high (MSI-H) mCRC.

Main Results:

• EGFR inhibitors (cetuximab, panitumumab) improve survival by ~6 months in KRAS/NRAS/BRAF wild-type left-sided mCRC.
• Bevacizumab (VEGF inhibitor) is an alternative for right-sided tumors or second-line therapy.
• BRAF-mutated mCRC may benefit from combination therapy (encorafenib, binimetinib, cetuximab), extending survival by ~3 months.
• Immunotherapy (pembrolizumab) significantly improves progression-free survival in MSI-high mCRC.

Conclusions:

• Targeted therapy is indicated for specific unresectable mCRC patient subsets.
• Genomic profiling is crucial for selecting appropriate treatments, including EGFR inhibitors, VEGF inhibitors, and immunotherapy.
• Treatment decisions for mCRC should be personalized based on tumor genetics and characteristics.